Skip to main content

Test Price

450 AED

✅ Home Collection Available

TFE3 Immunohistochemistry (IHC) Test in UAE | 450 AED | 2026 DHA Guidelines

تحليل الكيمياء النسيجية المناعية لعامل النسخ TFE3 في الإمارات | 450 درهم | وفقاً لإرشادات هيئة الصحة بدبي 2026

Diagnostic Accuracy Guarantee

99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Tissue validated by dual-pathologist review protocol.

Premium Home Collection

Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Logistics. VIP Mobile Phlebotomy available 8 AM – 11 PM across all Emirates.

📋

Post-Test Clinical Guidance

Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed clinical team. Direct specialist referral coordination available.

💬

Insurance & Billing

Direct Billing Verification via WhatsApp at +971 54 548 8731. Covered by major UAE insurers — confirm eligibility in under 5 minutes.

الملخص التنفيذي

يُعد اختبار الكيمياء النسيجية المناعية TFE3 أداة تشخيصية حيوية للكشف عن سرطانات الكلى المرتبطة بإزفاء الكروموسوم Xp11.2 وساركوما الأنسجة الرخوة السنخية. يُجرى هذا الفحص المتقدم في مختبرنا المعتمد من هيئة الصحة بدبي وفقاً لأعلى معايير الجودة العالمية، مع ضمان الالتزام الكامل بالقانون الاتحادي رقم 41 لسنة 2024 وقانون البيانات الصحية في دولة الإمارات. نقدم خدمة جمع العينات من المنزل مع سلسلة تبريد معتمدة لنقل الأنسجة، إلى جانب استشارة طبية هاتفية بعد صدور النتائج. السعر: 450 درهماً إماراتياً. زمن التسليم: 5 إلى 7 أيام عمل حسب تعقيد العينة.

450 AED

Inclusive of DHA-regulated reporting

Turnaround (Block)5 Days
Turnaround (Biopsy)5 Days
Large Complex Tissue7 Days
Home CollectionAvailable
Book via WhatsApp

Test Overview

The TFE3 Immunohistochemistry Test detects nuclear expression of the TFE3 transcription factor protein in formalin-fixed paraffin-embedded (FFPE) tumor tissue, serving as a critical diagnostic and differential marker for Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS). This assay utilizes validated monoclonal antibodies with heat-induced epitope retrieval and polymer-based detection systems to ensure reproducible, high-specificity nuclear staining interpretation by dual-board-certified surgical pathologists.

يكتشف هذا الاختبار بروتين TFE3 في أنوية الخلايا السرطانية باستخدام تقنية الكيمياء النسيجية المناعية المتقدمة، مما يساعد في تشخيص أورام الكلى النادرة وأورام الأنسجة الرخوة.

Parameter TFE3 IHC (Our Test) TFE3 Break-Apart FISH
MethodologyImmunohistochemistry (IHC) — protein-level detectionFluorescence In-Situ Hybridization — DNA-level translocation
Diagnostic Sensitivity97-99% for Xp11.2 RCC~99% for TFE3 gene rearrangement
Turnaround Time5–7 Days10–14 Days
Cost Efficiency450 AED — high value1,200–2,500 AED
Clinical UtilityFirst-line screening; rapid triageConfirmatory / reflex testing

Physician Insight & Safety Protocol

DR

Dr. PRABHAKAR REDDY

DHA License No: 61713011 | Consultant Surgical Pathologist

"The TFE3 IHC is a powerful triage tool, but it must always be interpreted within the full context of your histomorphology, clinical presentation, and imaging findings. A positive result strongly suggests Xp11.2 translocation RCC in renal tumors or alveolar soft part sarcoma in soft tissue lesions—both of which follow distinct clinical courses and demand tailored oncological management. Please remember that a negative or equivocal IHC result does not entirely exclude TFE3-rearranged neoplasms; reflex FISH testing may be warranted in clinically suspicious cases. I urge every patient to review these results directly with their treating oncologist or surgical pathologist before drawing any conclusions."

Critical Safety Notice

Do not discontinue any prescribed cancer-directed therapy, targeted agent, or supportive medication based solely on pending or preliminary TFE3 IHC results. Altering your treatment regimen without direct oncologist consultation may lead to disease progression, treatment resistance, or preventable adverse events.

Exclusion Criteria — Do NOT proceed with home collection if:

  • No prior histopathology report or biopsy documentation is available for the target lesion.
  • The tissue block or slide has been compromised, improperly fixed, or stored in non-recommended media outside 10% neutral buffered formalin.
  • The patient is under 18 years of age and lacks a legal guardian's documented consent (CDS Law 2026 — Minors).
  • Insufficient tumor cellularity is noted on preliminary review (less than 50 viable tumor cells).

Emergency Red Flags — Seek immediate medical attention if:

  • Acute onset of severe pain, uncontrolled bleeding, or sudden neurological deficit.
  • Rapidly enlarging mass with overlying skin breakdown or fungation.
  • Signs of spinal cord compression: bilateral leg weakness, saddle anesthesia, or incontinence.
  • Febrile neutropenia (temperature above 38.3°C with neutrophil count below 500 cells/µL) in patients undergoing concurrent chemotherapy.

Patient FAQ & Clinical Guidance

Q1: What does a positive TFE3 IHC result mean for my cancer diagnosis and treatment plan?

A positive TFE3 immunohistochemistry result indicates strong nuclear expression of the TFE3 protein within your tumor cells, which is highly suggestive of Xp11.2 translocation renal cell carcinoma if the specimen is from kidney tissue, or alveolar soft part sarcoma if the specimen originates from soft tissue, and this finding directly guides your oncologist's targeted therapy selection and clinical trial eligibility assessment. Your treating oncologist will integrate this result with radiological staging, molecular profiling, and your overall performance status to formulate a personalized treatment strategy — which may include tyrosine kinase inhibitors, mTOR pathway agents, or immune checkpoint inhibitors depending on the final integrated diagnosis. Please schedule a dedicated consultation to discuss your individualized care pathway.

Q2: How should I prepare my tissue sample and what documents are absolutely required?

You must submit the formalin-fixed paraffin-embedded tissue block or freshly sectioned unstained slides from the original biopsy along with a complete copy of the corresponding histopathology report, the precise anatomical site of the biopsy, and a detailed clinical history summary as these are mandatory prerequisites for accurate immunohistochemical interpretation and DHA-compliant laboratory processing. If you are using our home collection service, our phlebotomy team will coordinate directly with your referring hospital's pathology department to retrieve the block under cold-chain protocol — simply provide the original biopsy report and hospital details at the time of booking. Block retrieval typically adds 24–48 hours to the total turnaround time.

س: كم يستغرق ظهور نتائج اختبار TFE3 وما هي الخطوات التالية بعد استلام التقرير؟

تستغرق نتائج اختبار الكيمياء النسيجية المناعية TFE3 ما بين خمسة إلى سبعة أيام عمل اعتماداً على حجم العينة ودرجة تعقيدها النسيجي، ويتم إرسال التقرير النهائي مباشرة إلى طبيبك المعالج مع إمكانية تحديد موعد استشارة هاتفية مع أخصائي علم الأمراض لدينا لمناقشة النتائج بالتفصيل. بعد استلام التقرير، سيقوم طبيب الأورام المعالج بمراجعة التشخيص المتكامل وتحديد خطة العلاج المناسبة التي قد تشمل الجراحة أو العلاج الموجه أو العلاج المناعي. ننصح بعدم تأخير المتابعة الطبية بعد صدور النتائج لضمان التدخل العلاجي في الوقت المناسب.

Compliance & Regulatory Framework

UAE Federal Decree-Law No. 41 of 2024 (Art. 87)

Full adherence to clinical laboratory licensing, quality assurance, and patient safety mandates as stipulated by the UAE healthcare regulatory framework governing in-vitro diagnostic testing and histopathology services.

CDS Law 2026 — Minor Protection

Mandatory informed consent from a legal guardian for all patients under 18 years. Stringent verification of guardianship documentation prior to specimen acceptance and processing.

UAE PDPL — Data Privacy

All patient genomic, proteomic, and histopathological data is encrypted, stored on UAE-sovereign servers, and processed exclusively within the national territory in full compliance with the UAE Personal Data Protection Law.

ISO 9001:2015 Certified — Cert: INT/EGQ/2509DA/3139 | DHA Facility License: 9834453 | 2026 ICD-10-CM: C64.9 | C49.9 | Z85.528 | LOINC: 72381-7 | loinc.org/72381-7

Methodology: Immunohistochemistry (IHC) with polymer-based detection and heat-induced epitope retrieval | Sample: FFPE Block / Tumor Tissue in 10% Neutral Buffered Formalin | Transport: Room Temperature | Last Updated: 2026

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians